
    
      This is a 4-week efficacy, safety and tolerability study of MSRD-100 applied twice daily for
      4 weeks compared to its vehicle among subjects ≥3 months of age in the treatment of atopic
      dermatitis covering ≥5% body surface area.

      The study will consist of up to 4 visits which includes Screening - Visit 1 (Screening),
      Baseline - Visit 2 , Visit 3 (Day 14), and an End of Treatment/Final Study Visit - Visit 4
      (Day 28).

      Study IDs M169981001 and M169981002 are two identical studies being run in parallel with
      different study sites.
    
  